Home Newsfeeds Wolfe Research Downgrades Southern Copper to Underperform

Wolfe Research Downgrades Southern Copper to Underperform

Wolfe Research analyst Timna Tanners downgrades Southern Copper (NYSE:SCCO) from Peer Perform to Underperform.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Wolfe Research analyst Timna Tanners downgrades Southern Copper (NYSE:SCCO) from Peer Perform to Underperform.

Analyst Ratings

Expert Ratings for ConocoPhillips

By Benzinga Insights

March 23, 2:00 PM

Over the past 3 months, 10 analysts have published their opinion on ConocoPhillips (NYSE:COP) stock. These analysts are…

COP

Lucy Scientific Secures First Delivery Of Psilocybin To Israel Following DMT & 5-MeO-DMT

By Lara Goldstein

February 28, 6:29 PM

Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a Canada-based psychedelics manufacturing company, has inked its first commercial sale to the prestigious Hadassah BrainLabs, also known as the Center for Psychedelics Research at the Hadassah Medical Center at Hebrew University in Jerusalem.

LSDI

Scotiabank Downgrades Kilroy Realty to Sector Perform, Lowers Price Target to $43

By Benzinga Newsdesk

January 24, 8:14 AM

Scotiabank analyst Nicholas Yulico downgrades Kilroy Realty (NYSE:KRC) from Sector Outperform to Sector Perform and lowers the price target from $53 to $43.

KRC

M&A
News

Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific

By Benzinga Newsdesk

October 3, 7:39 AM

Lokavant, the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across the

ROIV

Wolfe Research Downgrades Southern Copper to Underperform

Related Posts

Expert Ratings for ConocoPhillips

Lucy Scientific Secures First Delivery Of Psilocybin To Israel Following DMT & 5-MeO-DMT

Scotiabank Downgrades Kilroy Realty to Sector Perform, Lowers Price Target to $43

Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific